Tharimmune
We have no price for Tharimmune since 18 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Tharimmune vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tharimmune | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Tharimmune's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -0.79 | -0.42 | −88.1% |
| Nov 12, 2025 | -0.34 | -0.43 | +20.9% |
| Aug 14, 2025 | -0.64 | -0.58 | −10.3% |
| May 12, 2025 | -0.99 | -0.84 | −17.9% |
| Mar 25, 2025 | -2.02 | -1.53 | −32.0% |
| Nov 7, 2024 | -2.45 | – | – |
| Aug 9, 2024 | -2.42 | – | – |
| May 9, 2024 | -2.85 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Tharimmune
Is Tharimmune a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tharimmune AI analysis
What does Tharimmune do?
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. It is in Biotechnology.
Who are Tharimmune's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Tharimmune's.
Prices: daily closes to May 18, 2026. Fundamentals: company reports via invest-like data.